Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to evaluate the safety and clinical activity of nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors refractory to prior PD-(L)1 therapy.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
42 participants in 3 patient groups
Loading...
Central trial contact
Joann Santmyer, RN; Colleen Apostal, RN
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal